CompletedNot Applicable

Efficacy and Safety of 30% Salicylic Acid and 10% Nicotinamide Combined Therapy in Melasma

China56 participantsStarted 2021-01-01

Plain-language summary

This prospective, randomized, placebo-controlled study evaluated the synergistic effects of 30% salicylic acid (SA) chemical peels and topical 10% nicotinamide (NAM) in 56 patients with moderate-to-severe melasma. Participants were divided into four groups: placebo control, SA peels alone (every 2 weeks for 8 sessions), NAM cream alone (twice daily for 16 weeks), and combination therapy (SA+NAM). The investigators investigated the efficacy and safety of 30%SA chemical peeling combined with 10% NAM.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Males and nonpregnant females, aged 18-60 years old;
✓. Diagnosed with melasma;
✓. Patients with good cognitive function and normal mental status;
✓. Patients with good communication skills;
✓. Voluntary participation in the study and signing of informed consent form.

Exclusion criteria

✕. pregnancy or lactation;
✕. pigmentation from other causes, such as hormonal dermatitis, cosmetic dermatitis, etc;
✕. established allergy to SA or NAM;
✕. active skin infection;
✕. systemic diseases, such as immunodeficiency disease, diabetes, lupus erythematosus, etc;
✕. having facial surgery, laser treatment, or whitening products in the past three months;
✕. neurological or psychiatric disorders.

What they're measuring

mMASI score

Timeframe: From enrollment to week 16

Trial details

NCT IDNCT07062120

SponsorSecond Affiliated Hospital of Xi'an Jiaotong University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-01

View on ClinicalTrials.gov More Melasma trials